Advertisement
Screener

Pyxis Oncology, Inc. (PYXS) Income (Loss) from Equity Method Investments

1.6 / 5 stars · 10/32 Roast Me

Pyxis Oncology, Inc. Income (Loss) from Equity Method Investments

Pyxis Oncology, Inc. (PYXS) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-22.

Discontinued › Income Statement › Other Income

us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2023-03-22

  • Pyxis Oncology, Inc. income (loss) from equity method investments for the quarter ending 2021-12-31 was $0.00.
  • Pyxis Oncology, Inc. income (loss) from equity method investments for the quarter ending 2021-09-30 was $0.00.
  • Pyxis Oncology, Inc. income (loss) from equity method investments for the quarter ending 2021-06-30 was -$231.00K.
  • Pyxis Oncology, Inc. income (loss) from equity method investments for fiscal 2022 was $0.00.
  • Pyxis Oncology, Inc. income (loss) from equity method investments for fiscal 2021 was -$231.00K.
Period endIncome (Loss) from Equity Method Investments 3 monthIncome (Loss) from Equity Method Investments 6 monthIncome (Loss) from Equity Method Investments 9 monthIncome (Loss) from Equity Method Investments 12 month
2022-12-31$0.00
10-K · filed 2023-03-22
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22
$0.00
derived: sum of 2 quarters · filed 2023-03-22
-$231.00K
derived: sum of 3 quarters · filed 2023-03-22
-$231.00K
10-K · filed 2023-03-22
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01
-$231.00K
derived: sum of 2 quarters · filed 2022-11-01
-$231.00K
10-Q · filed 2022-11-01
2021-06-30-$231.00K
10-Q · filed 2022-08-15
-$231.00K
10-Q · filed 2022-08-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55